We investigated the influence of age and co-morbidity on treatment, the occurrence of serious nonurological complications of treatment and prognosis for prostate cancer patients diagnosed and treated in community hospitals. Additional information from a random sample of 505 prostate cancer patients (aged 40 years or older) from the Eindhoven Cancer Registry diagnosed between 1995 and 1999 was collected. In all, 43% of the prostate cancer patients aged 40-69 years and 64% of those aged 70 or older suffered from one or more serious concomitant disease that barely affected primary treatment choice. However, compared to patients without co-morbidity, patients with cardiovascular diseases underwent radical prostatectomy less often (P ¼ 0.01). In all, 38% of the patients undergoing radical prostatectomy suffered from complications during the first year after diagnosis versus about 20% of those receiving radiotherapy. The number of complications did not seem to be affected by comorbidity. After adjustment for age, stage, grade, prostate-specific antigen level and treatment, the cumulative risk of death was almost two times higher for patients with two or more concomitant diseases than for patients without co-morbidity. After adjustment for age, prostate cancer patients with co-morbidity were not treated differently, did not suffer from more complications but had a worse prognosis, compared to those without co-morbidity.
Introduction
Prostate cancer is the most common tumour among males in the Netherlands and occurs mainly among the elderly. 1 More than 55% of the incident tumours occur in patients aged 70 years or older. Many older patients have co-morbid conditions in addition to their tumour. In a recent population-based study in the registration area of the Eindhoven Cancer Registry, the prevalence of at least one co-morbid disease increased from 33% of patients younger than 60 years to 58% of patients aged 80 years or older. 2 Older patients with co-morbidity are often treated less extensively, [3] [4] [5] [6] probably because these patients have a shorter life expectancy and an increased risk of complications. [7] [8] [9] [10] Treatment results for elderly prostate cancer patients are largely unknown, as most of these patients are excluded from clinical trials.
In this population-based study, we investigated the influence of age and co-morbidity on treatment, the occurrence of serious non-urological complications of treatment and prognosis for prostate cancer patients.
Patients and methods
The Eindhoven Cancer Registry collects data on all patients with newly diagnosed cancer in the southeastern part of the Netherlands. The registry now serves a population of 2.3 million inhabitants. The estimated completeness of the cancer registry in the Netherlands is more than 95%. 11 The area offers good access to specialized medical care in 10 general hospitals and two large radiotherapy institutes. For this study, a random sample was taken from the database of the Eindhoven Cancer Registry. This sample consisted of 543 men aged 40 years or older with prostate cancer, diagnosed between 1995 and 1999 when there was a modest degree of opportunistic screening. Of these 543 patients, 38 patients were excluded for the following reasons: 30 clinical records could not be found in the hospitals owing to migration, death or unknown reasons and eight clinical records were incomplete. These excluded patients who had a mean age of 72 years (compared to 71 years for those in the study) and 68% of the 38 patients had died during follow-up (compared to 51% of those in the study).
Information on diagnosis, staging, co-morbidity and treatment was extracted from the medical records by trained registrars. The medical record is generally regarded as the most complete source of information on the patient's past and current health status.
12 Serious co-morbidity was recorded according to a slightly modified version of the index developed by Charlson et al. 13 Only co-morbid conditions with potential negative prognostic effect were included ( Table 1 ). The data were extracted from previous admissions, letters from and to other specialists, medical history and preoperative screening. Co-morbidity was defined as diseases that were present at the time of cancer diagnosis.
Clinical stage was recorded in the registry according to the TNM classification in use.
14 As pathological stage is only available after radical prostatectomy and treatment decisions are based on clinical stage, only the latter was used (except for lymph node involvement and distant metastasis, which were also based on pathological stage). The clinical tumour classification was simplified as T1, T2, T3, T4 or as 'unknown' (Tx) when insufficient information was available for accurate staging. In case of lymph node involvement (N1) or distant metastases (M1), stage was defined as metastasized. Histological grading was recorded according to the TNM classification of malignant tumours.
14 Patients with undifferentiated tumours (o1%) were included in the category 'poorly differentiated tumours' (G3) in the analyses.
Treatment was classified as radical prostatectomy (usually retro pubic), radiotherapy, hormonal therapy only, no treatment (including transurethral resection of the prostate), and 'other (such as lymphadenectomy) or unknown'. Patients undergoing a radical prostatectomy followed by any other adjuvant therapy, such as radiotherapy or hormonal therapy, were included in the radical prostatectomy group. Patients who received radiotherapy and hormonal therapy were included in the radiotherapy group.
With the approval of the treating physicians, additional information was extracted from the medical records on complications within 1 year of diagnosis and prostate-specific antigen (PSA) level. The following serious complications during the first year after diagnosis were recorded: minor infections (such as superficial wound infection), major infections (such as abscess and septicaemia), haemorrhage (requiring blood transfusion or surgery), thrombo-embolic complications, cardiac problems (such as cardiac insufficiency), cerebral problems (such as cerebrovascular accident), complications owing to radiotherapy (such as proctitis) and other events (including strictures and poorly defined conditions). Impotence and incontinence could not be recorded, because no reliable information about these complications can be extracted from the medical records.
Prostate-specific antigen level (ng/ml) at diagnosis was extracted from the medical record and divided into three groups: o4.0, 4.0-10.0 and 410.0 ng/ml.
Information on vital status of the patients was obtained from the hospital records, the municipal registries in the registration area and the death register of the Central Bureau for Genealogy (an institution that registers all deceased individuals in the Netherlands via the municipal civil registers). Follow-up was complete up to 1 January 2005 (mean follow-up 4.8 years).
The association between co-morbidity on the one hand and treatment and number of complications (0, 1 and X2) on the other hand was analysed according to age. Differences between subgroups were tested with the w 2 -test. Survival time was defined as the time from diagnosis until death or the end of the study (1 January 2005) . Univariate crude 5-year survival rates were calculated according to age, co-morbidity, stage, grade, PSA level at diagnosis and treatment. Differences in crude survival between categories were tested with the log-rank test. In a multivariable Cox proportional hazard regression analysis, the independent hazard ratios for age at diagnosis, co-morbidity, stage, grade and PSA level at diagnosis were first estimated in a model without treatment. Then, treatment was included in the model to investigate whether the prognostic effects of age and comorbidity could be fully explained by less aggressive treatment.
The SAS computer package (version 8.2) was used for all statistical analyses (SAS Institute Inc., Cary, NC, USA, 1999).
Results
The distribution of age, stage and vital status in the random sample was similar to that in the whole database of the Eindhoven Cancer Registry. In total, 220 patients were between 40 and 69 years and 285 patients were 70 years or older.
The clinical characteristics of the prostate cancer patients are shown in Table 2 . Patients aged 70 years or Co-morbidity, complications and prostate cancer S Houterman et al older presented with more co-morbid diseases compared to patients aged 40-69 years (Po0.01). The most common condition in both age groups was cardiovascular disease (13% of patients aged 40-69 years and 29% of patients aged 70 years or older; Po0.01). Previously, cancer (11%) was more prevalent in patients aged 70 years or older compared to patients aged 40-69 years (6%; Po0.05).
The proportion of patients undergoing radical prostatectomy was significantly lower in patients aged 70 years or older (Po0.01; Table 2 ) and also the proportion of patients receiving curative radiotherapy was somewhat lower in this age group (P ¼ 0.03). Hormonal treatment was administered more to those aged 70 years or older (Po0.01). The proportion of patients aged 40-69 years who received no antitumour treatment ('watchful waiting') increased from 19% of patients with a T1 and 4% of patients with a T2 tumour to 44 and 18%, respectively, of patients aged 70 years or older (Po0.01). The number of co-morbid conditions did not affect the treatment chosen in either age group (P ¼ 0.93 and 0.52, respectively, Figure 1 ). However, patients with cardiovascular diseases underwent prostatectomy significantly less often (6%) and hormonal therapy significantly more often (48%) than patients without co-morbidity (18 and 26%, respectively, P ¼ 0.01).
Among patients undergoing radical prostatectomy, 38% suffered one or more non-urological complications during the first year after diagnosis in both age groups (26 patients aged o70 years and three patients aged X70 years; P ¼ 1.0). The most common complication was minor infection (14% in those aged o70 years (N ¼ 10) and 25% in those aged X70 years (N ¼ 2); P ¼ 0.4). In patients younger than 70 years, 26% had other complications like strictures. Among those receiving radiotherapy, the proportion of patients with a complication was 22% of those aged 40-69 years and 19% of patients aged 70 years or older (19 patients aged o70 years and 17 aged X70 years; P ¼ 0.8). Most of these complications were radiotherapy-related complications such as proctitis. There was no relationship between the number of complications and co-morbidity for either patients undergoing radical prostatectomy or those receiving radiotherapy (P ¼ 0.8 and 0.7, respectively; Figure 2) .
Five-year crude survival decreased from 81% for patients aged 40-69 years to 50% for those aged 70 years or older (Po0.01; Table 3 ). Even for patients without comorbidity, the survival rate was significantly lower for elderly than for younger patients. The survival rate decreased significantly with increasing number of concomitant diseases in both age groups (Po0.01 and P ¼ 0.02, respectively). Age, co-morbidity, stage and grade were independent prognostic factors in a multivariable analysis. Including treatment in the model did not alter the estimates. The risk of dying was 1.9 times higher for patients aged 70 years or older compared to patients younger than 70 years. Patients with two or more concomitant diseases had an almost two times higher risk of dying compared to those without comorbidity, after adjustment for age, stage, grade, PSA level and treatment.
Discussion
This population-based study shows that 43% of the prostate cancer patients aged 40-69 years and 64% of Co-morbidity, complications and prostate cancer S Houterman et al those aged 70 years or older suffered from one or more serious concomitant disease. Patients with co-morbidity were not treated differently and did not suffer from more non-urological complications compared to patients without co-morbidity. However, patients with cardiovascular diseases underwent prostatectomy less often compared to patients without co-morbidity. As expected, comorbidity was an independent predictor of survival. The increasing prevalence of co-morbidity with age does not entirely explain why elderly patients were treated less aggressively. Age seemed to have more influence on the treatment chosen than co-morbidity. Data from the Virginia Cancer Registry on 3117 men with local-regional prostate cancer diagnosed between 1985 and 1989 also showed that age, even after adjustment for co-morbidity, was the strongest predictor of treatment. 6 In a population-based study carried out in the southern part of the Netherlands between 1993 and 1996, treatment decisions were also determined largely by the patient's age and the experience of the urologist, instead of the patient's co-morbid conditions. 10 In contrast, other studies found that patients with co-morbidity were treated less aggressively (after adjustment for age). [3] [4] [5] [6] In a large population-based study of all prostate cancer patients diagnosed between 1995 and 2002 (N ¼ 6340) in the area of the Eindhoven Cancer Registry (from which our sample was derived), we found that prostate cancer patients aged 60-79 years were treated less aggressively in the presence of one or more co-morbid conditions. 2 An explanation for this discrepancy could be the relatively small sample size of the present study. In the present study, patients aged 40-69 years with two or more concomitant diseases received less radical prostatectomy compared to those with no or one concomitant disease, but this difference was not statistically significant. Probably, the treatment effect could be diluted in the present study, owing to the inclusion of patients aged younger than 60 years and over 80 years (in which no treatment effect was found in the former study). However, as was found in our previous study, 2 patients with cardiovascular diseases also underwent prostatectomy significantly less often and received hormonal therapy significantly more often than patients without co-morbidity (Po0.01). The same was found for 3073 participants of the Prostate Cancer Outcomes Study. 3 The prevalence of co-morbidity among older patients may be underestimated in this study, because older patients underwent surgery less often. In patients not undergoing surgery, co-morbid conditions might be missed because they undergo less (preoperative) examination.
The number of patients undergoing radical prostatectomy has increased over time owing to the increasing detection of early-stage prostate cancer. 15 As a result, the number of patients who are at risk for complications following prostatectomy has increased. However, surgical techniques and postoperative management have improved over time, resulting in fewer complications. 9 In this study population, no one died during or after radical prostatectomy. It is difficult to compare the prevalence of postoperative complications between studies, because of small sample sizes in most studies, differences in classification of complications, clinical setting and changes in care over the years. Few studies have investigated the effect of co-morbidity on postoperative complications [7] [8] [9] 16, 17 and, to our knowledge, no studies have examined the effect of co-morbidity on complications in prostate cancer patients undergoing only radiotherapy. In our study, we found no association between co-morbidity and the number of complications after prostatectomy or radiotherapy. This confirms the results of two previous studies, in which co-morbidity and age did not significantly affect complications following prostatectomy. 7, 8 A study among 472 patients with localized prostate cancer carried out in a general hospital in Texas showed that, in particular, major complications following prostatectomy were related to co-morbidity and not to age. 9 However, an explanation for the discrepancy could be that they used a different classification system for co-morbidity (ASA classification). In a study among more than 11 000 men carried out in Canada, it was found that increasing co-morbidity (using Diagnosis Count as co-morbidity index) was a stronger predictor than age of complications within 30 days following radical prostatectomy. Co-morbidity, complications and prostate cancer S Houterman et al
We could not include impotence and incontinence as a complication, because these cannot be reliably extracted from the medical records and should be assessed by questionnaire.
As was also found in other studies, prognosis for patients and co-morbidity was significantly worse compared to patients without co-morbidity, after adjustment for age, tumour characteristics and treatment. 2, [18] [19] [20] [21] [22] [23] This means that the observed differences in survival between patients with and without co-morbidity could not be (fully) explained by these variables. The negative influence of co-morbidity on survival might be owing to several mechanisms, such as the increased risk of death owing to the co-morbid condition itself. We had no data on cause of death of our patients, so we could not investigate this hypothesis.
In conclusion, this study shows that prostate cancer patients with co-morbidity were not treated differently, did not suffer from more non-urological complications following treatment, but had a worse prognosis compared to patients without co-morbidity after adjustment for age, tumour characteristics and treatment. Age seemed to be more important for urologists when deciding whether a patient is eligible for prostatectomy or curative radiotherapy than their co-morbid conditions. Co-morbidity, complications and prostate cancer S Houterman et al
